Finance Watch: Vir Restructures, Adds Sanofi Cancer Drugs To Clinical-Stage Pipeline
New Strategy Cuts 25% Of Workforce
Restructuring Edition: Vir will end influenza, COVID-19 and T-cell-based viral vector platform programs to focus on clinical hepatitis and cancer assets. Also, FibroGen cut 75% of its workforce after a clinical trial failure, while Arbutus, HilleVax, Pfizer and others also announced layoffs.
